| 22nd week of 2010 patent applcation highlights part 52 |
| Patent application number | Title | Published |
|---|
| 20100137185 | POWDER DETERGENT GRANULE CONTAINING ACIDIC WATER-SOLUBLE POLYMER AND MANUFACTURING METHOD THEREOF - The present invention relates to powder detergent granules that are substantially free of a water-insoluble component such as zeolite or silica, a method for manufacturing the powder detergent granules and a copolymer having various properties useful as a detergent component. The powder detergent granules of the present invention are substantially free of a water-insoluble component, and thus exhibit good solubility and washing performance (stain removal performance) in cold water, do not leave residue after laundry, and reduce the likelihood of a caking phenomenon during manufacture and storage. And, the powder detergent granules of the present invention are substantially free of zeolite or silica that absorbs a liquid component, but are capable of accommodating a considerable amount of liquid surfactant. Further, a copolymer comprising acrylic acid monomer unit and 2-acrylamido-2-methylpropane sulfonic acid monomer unit, an acidic water-soluble polymer of the present invention, is useful as a detergent component in various aspects. | 2010-06-03 |
| 20100137186 | USE OF AN ACTIVE PRINCIPLE ORIGINATING FROM AMARANTH (AMARANTHUS) FOR PREPARING A COMPOSITION INTENDED TO ACTIVATE CELLULAR ENERGY AND TO PROTECT THE SKIN FROM OXIDATIVE DAMAGE - Methods of administering in a cosmetic composition or a pharmaceutical composition, an effective amount of a peptide active principle originating from amaranth of the species | 2010-06-03 |
| 20100137187 | Glutamate-Enhanced Cell-Penetrating Peptides and Methods of Using Same - Disclosed herein are novel glutamate-enhanced cell-penetrating peptides (CPPs) for use as delivery vehicles to mediate intracellular uptake of therapeutic payloads and methods of using the same. | 2010-06-03 |
| 20100137188 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS - This invention relates to the use of a cyclic compound of formula (I) | 2010-06-03 |
| 20100137189 | MODIFIED GLOBIN PROTEINS WITH ALTERED ELECTRON TRANSPORT PATHWAY - The present invention relates to a modified porphyrin-based oxygen-carrying protein, such as haemoglobin, which has been found, in its unmodified state to have a low affinity site of electron transfer and a high affinity electron transfer between a reductant and ferryl haem iron via one or more protein amino acids. The invention provides such proteins that comprise a modification to enhance this pathway. | 2010-06-03 |
| 20100137190 | LIQUID COMPOSITION FOR EXTERNAL APPLICATION AND PREPARATION FOR EXTERNAL APPLICATION FOR TREATMENT OF SKIN ULCER - An object of the present invention is to provide a liquid composition for external application and a preparation for external application which are excellent in healing effect on skin ulcers including intractable skin ulcers such as bedsore (decubitus), diabetic skin ulcer and ischemic skin ulcer. The liquid composition for external application of the present invention as means for the resolution is characterized by comprising at least G-CSF (a granulocyte colony stimulating factor) as an active ingredient and 0.001% to 5% of alginic acid. The preparation for external application for treatment of a skin ulcer of the present invention is characterized by comprising the liquid composition for external application of the present invention as a medicinal ingredient. | 2010-06-03 |
| 20100137191 | PROTECTIVE AGENTS FOR TRANSPLANTED ORGANS - Compositions for protecting transplanted organs, promoting survival of transplanted organs or preserving organs for transplant containing erythropoietin (EPO) as an active ingredient are provided. | 2010-06-03 |
| 20100137192 | COMPOSITIONS AND METHODS FOR TREATING OR AMELIORATING MYCOBACTERIAL INFECTIONS - A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram poitive and acid fast bacilli in general and tuberculosis (TB), | 2010-06-03 |
| 20100137193 | CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH - Described herein are methods of inhibiting the growth of or killing a bacterium in an animal subject, preventing or delaying onset of an infection with a bacterium in an animal subject, preventing or delaying onset of a pathogen mediated disease or disorder in an animal subject, or reducing bacterial load in an animal subject, comprising administering an effective amount of a derivatized chitosan to the animal. Also described herein are preparations comprising a chitosan derivative for administration to an animal. | 2010-06-03 |
| 20100137194 | Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism - The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels. | 2010-06-03 |
| 20100137195 | Production of Recombinant IL-18 Binding Protein - The invention relates to a process for the production of IL-18 binding protein (IL-18BP), and to a composition comprising IL-18BP characterized by a specific glycosylation pattern. | 2010-06-03 |
| 20100137196 | HISTONE DEACETYLASES, AND USES RELATED THERETO - The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell proliferation and differentiation in vitro and in vivo. | 2010-06-03 |
| 20100137197 | LYOPHILIZED ANTI-FUNGAL COMPOSITION - A lyophilized anti-fungal composition comprises (A) caspofungin, or a pharmaceutically acceptable salt thereof, in an effective amount; (B) one or more non-reducing sugars having a glass transition temperature T | 2010-06-03 |
| 20100137198 | PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION - A pharmaceutical or cosmetic carrier or composition for topical application characterized by rheological properties which render the carrier or composition semi-solid at rest and a liquid upon application of shear forces thereto. The composition or carrier are prepared by mixing 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, by weight, wherein at least one of them has therapeutic or cosmetic benefits, in the presence or absence of a biologically active substance. | 2010-06-03 |
| 20100137199 | Dab9 DERIVATIVES OF LIPOPEPTIDE ANTIBIOTICS AND METHODS OF MAKING AND USING THE SAME - The present invention provides Dab | 2010-06-03 |
| 20100137200 | METHODS FOR TREATMENT OF GROWTH DISORDERS - The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having an endocrine disorder characterized by partial endogenous growth hormone activity or signaling. The invention provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) effective to improve metabolism in the patient, where the patient receives IGF-1 in a single daily administration. The invention also provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) and an amount of growth hormone (GH) that in combination are effective to improve growth or metabolism in the patient, where the patient receives IGF-1 in a single daily administration and receives GH in a single daily administration, and where the single IGF-1 administration and the single GH ad-ministration are administered to the patient substantially contemporaneously each day. | 2010-06-03 |
| 20100137201 | MEDICAMENTS - There is provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention, reduction or inhibition of scarring. There is also provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention and/or treatment of a fibrotic disorder. Further aspects relate to methods by which scarring may be prevented, reduced or inhibited, and by which fibrotic disorders may be prevented and/or treated. Therapeutically effective amounts of WNT5A, or its fragments or derivatives, that may be used in the medicaments or methods of the invention are also provided. | 2010-06-03 |
| 20100137202 | COMPOSITIONS FOR REPROGRAMMING A CELL AND USES THEREFOR - The present invention generally provides therapeutic compositions and methods for treating a disease, disorder, or injury characterized by a deficiency in the number or biological activity of a cell of interest. The method provides compositions for generating reprogrammed cells or for increasing regeneration in a cell, tissue, or organ of interest. Such methods are useful for treating subjects having a deficiency in a particular cell type or in a polypeptide produced by that cell type. In particular, the invention provides prophylactic and therapeutic methods and compositions for ameliorating or preventing hyperglycemia associated with type I and type II diabetes and related complications. | 2010-06-03 |
| 20100137203 | METHOD FOR PREPARING A CELL-DERIVED EXTRACELLULAR MATRIX MEMBRANE - The present invention relates to a method for preparing a cell-derived extracellular matrix membrane, more particularly, to a method for preparing a chondrocyte-derived ECM membrane, the method comprising the steps of forming a suitable thickness of ECM membrane by culturing chondrocytes derived from animal cartilage at a high concentration in vitro, and drying it after decellularization process. The cell-derived ECM membrane scaffold according to the present invention is composed of extracellular matrix secreted by chondrocytes so that the membrane has excellent biocompatibility as well as an immune-previlage effect specific to cartilage. Since the membrane also has a suitable compressive strength, it can be used to replace periosteum for cartilage regeneration or artificial collagen membrane and used as dura mater transplant material, a natural ECM membrane for treating skin loss, materials for cell transplantation and a growth factor delivery vehicle. | 2010-06-03 |
| 20100137204 | GLP-1 PHARMACEUTICAL COMPOSITIONS - The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues. | 2010-06-03 |
| 20100137205 | Use of FGF-18 Protein, Target Proteins and Their Respective Encoding Nucleotide Sequences to Induce Cartilage Formation - The use of fibroblast growth factor (FGF)-18 protein, certain of its downstream target genes and respective expressed proteins, in particular sonic hedgehog (Shh), Shh protein, β-catenin, β-catenin protein, and the Wnt family of proteins that stimulate β-catenin, and the respective nucleotide sequences encoding this protein, particularly for inducing cartilage formation, particularly for the purpose of generating, repairing, reconstructing, or de novo formation of, cartilaginous tissue. Therapies for which FGF-18 and the target proteins are useful include repair and reconstruction of various tissues in conducting airways such as the trachea, bronchi, lung and larynx caused by, for example, tracheal-bronchial abnormalities, tracheal-laryngo or bronchial malaria. Other therapies for which FGF-18 and the target proteins would be useful include other cartilaginous tissues, such as those of joint and skeletal tissue caused by, for example, arthritis and meniscus abnormalities in joints. | 2010-06-03 |
| 20100137206 | NOVEL LIGAND GUIDED BLOCK COPOLYMERS FOR TARGETED DRUG DELIVERY - This application relates to micelle-forming poly(ethylene oxide)-block-poly(ester) block copolymers having reactive groups on both the poly(ethylene oxide) block and the poly(ester) block therein. The biodegradability of these copolymers and their biocompatibilities with a large number of bioactive agents make them suitable as carriers for various bioactive agents. The bioactive agent, such as DNA, RNA, oligonucleotide, protein, peptide, drug and the like, can be coupled to the reactive groups on the polyester block of the copolymer. A variety of targeting moieties can be coupled to the reactive group on the poly(ethylene oxide) block for targeting the bioactive agent to a particular tissue. The application also relates to a composition and method of use thereof for delivering bioactive agents. | 2010-06-03 |
| 20100137207 | G PROTEIN COUPLED RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF ACTIVATING AND INHIBITING G PROTEIN COUPLED RECEPTORS USING THE SAME - The invention relates generally to G protein coupled receptors and in particular to agonists and antagonists of G protein receptors and methods of using the same. | 2010-06-03 |
| 20100137208 | INTRATUMORALLY ADMINISTERED LACTOFERRIN IN THE TREATMENT OF MALIGNANTNEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES - The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies. | 2010-06-03 |
| 20100137209 | MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 AND METHODS BASED THEREON - The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (PAI-1) in which two or more amino acid residues that do not contain a sulfhydryl group have been replaced with amino acid residues that contain a sulfhydryl group and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified PAI-1 proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified PAI-1, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic. The modified PAI-1 molecules of the present invention are useful for the treatment, prophylaxis, management and amelioration of cardiovascular diseases such as, but not limited to those that are related to hyperfibrinolysis, hemophilia, and vessel leakage syndrome. | 2010-06-03 |
| 20100137210 | Gastrointestinal proliferative foctor and uses thereof - The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor (GIPF) polynucleotides and polypeptides. The invention further relates to the therapeutic use of GIPF to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa. | 2010-06-03 |
| 20100137211 | METHODS AND COMPOSITIONS FOR INTRA-ARTICULAR COAGULATION PROTEINS - The present invention provides methods and compositions for treating blood clotting factor disorders and/or reducing bleeding-associated joint damage by treatments delivered to the joint in a subject. | 2010-06-03 |
| 20100137212 | USE OF GLP-1 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS - The present invention describes the methods of using incretin mimetics such as GLP-1 receptor agonists, particularly exenatide, to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders. | 2010-06-03 |
| 20100137213 | FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES - The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed. | 2010-06-03 |
| 20100137214 | CHIMERIC HIRUDIN PROTEINS - The present invention relates to a chimeric hirudin protein comprising a carrier attached to the N-terminus of hirudin, with an intervening plasmin cleavage site. The chimeric hirudin protein contains a relatively inactive form of hirudin. However, when such chimeric hirudin protein being cleaved by plasmin in the vicinity of a clot and, ultimately causing the release of active hirudin and the reduction of the size of the clot. The chimeric hirudin protein exhibited much slower clearance in mice than unfused wild-type hirudin. | 2010-06-03 |
| 20100137215 | NOVEL TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES - This invention relates to novel tetrahydro-1H-pyrido[4,3-b]indoles, their derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by NMDA antagonists, acetylcholinesterase inhibitors, 5-HT6 antagonists, other neuroprotectors, antihistamines and agents that delay age-related pathologies and conditions. | 2010-06-03 |
| 20100137216 | AXMI-027, AXMI-036 AND AXMI-038, A FAMILY OF DELTA-ENDOTOXIN GENES AND METHODS FOR THEIR USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated delta-endotoxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NOS:2, 11 and 13, or the nucleotide sequences set forth in SEQ ID NOS:1, 10 and 12, as well as variants and fragments thereof. | 2010-06-03 |
| 20100137217 | FIBROSIS INHIBITOR FOR IMPLANTED ORGAN - A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy. | 2010-06-03 |
| 20100137218 | Expression System of NELL Peptide - Recombinant NELL peptides and methods of preparing the same are disclosed. | 2010-06-03 |
| 20100137219 | Methods and Compositions for Inhibiting Binding IgE to a High Affinity Receptor - The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy symptoms in mammals. | 2010-06-03 |
| 20100137220 | BLOOD SUGAR-MODULATING POLYPEPTIDES - A blood sugar-modulating polypeptide, a pharmaceutical composition comprising the polypeptide, and a method for modulating blood sugar in a mammal comprising the administration of the polypeptide are provided. The polypeptide has a following amino acid sequence or a homologous amino acid sequence derived from the substitution, deletion, and/or addition of one or more amino acids therein: | 2010-06-03 |
| 20100137221 | PEPTIDES THAT INTERACT WITH TOPOISOMERASE I AND METHODS THEREOF - Disclosed are compositions and methods for treating cancer comprising peptides that can act synergistically with chemotherapeutic agents. | 2010-06-03 |
| 20100137222 | Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents - The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection. | 2010-06-03 |
| 20100137223 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF - Provided herein are neuropeptide-2 receptor agonists of the formula (I): | 2010-06-03 |
| 20100137224 | METHOD OF REDUCING INJURY TO MAMMALIAN CELLS - A method of inhibiting the binding between N-methyl-D-aspartate receptors and neuronal proteins in a neuron the method comprising administering to the neuron an effective inhibiting amount of a peptide replacement agent for the NMDA receptor or neuronal protein interaction domain that effect said inhibition of the NMDA receptor neuronal protein. The method is of value in reducing the damaging effect of injury to mammalian cells. Postsynaptic density-95 protein (PSD-95) couples neuronal N-methyl-D-aspartate receptors (NMDARs) to pathways mediating excitotoxicity and ischemic brain damage. This coupling was disrupted by transducing neurons with peptides that bind to modular domains on either side of the PSD-95/NMDAR interaction complex. This treatment attenuated downstream NMDAR signaling without blocking NMDAR activity, protected cultured cortical neurons from excitotoxic insults and dramatically reduced cerebral infarction volume in rats subjected to transient focal cerebral ischemia. The treatment was effective when applied either before, or one hour after, the onset of excitotoxicity in vitro and cerebral ischemia in vivo. This approach prevents negative consequences associated with blocking NMDAR activity and constitutes practical therapy for stroke. | 2010-06-03 |
| 20100137225 | PHAGE DISPLAYED CELL BINDING PEPTIDES - This disclosure provides the construction, expression, and selection of the mutated genes that encode novel Trp cage polypeptides with desirable binding properties, as well as the novel Trp cage polypeptides themselves. The substances or targets bound by these novel Trp cage polypeptides may be but need not be proteins or polypeptides. Targets may include other biological or synthetic macromolecules as well as other organic and inorganic substances. Further, targets may also include a single or multiple cell or tissue types. The present invention achieves genetic variants of Trp cage-encoding nucleic acids through controlled random mutagenesis of the nucleic acids yielding a mixture of Trp cage polypeptides that are capable of binding targets. | 2010-06-03 |
| 20100137226 | FATIGUE-REDUCING AGENT - A pharmaceutical product, a functional food or the like has been demanded which can reduce the fatigue in a tired person and enables the tired person to lead a fulfilled life. Disclosed is a fatigue-reducing agent. The fatigue-reducing agent comprises ornithine or a salt thereof and glutathione or a salt thereof as active ingredients. | 2010-06-03 |
| 20100137227 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS - The invention relates to compositions comprising of SEQ NO: 1-244, 248-249, and any homologs, analogs, and fragments thereof. Such compositions can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient for administration to a human or a plant. The compositions can be administered topically or for systemic use. | 2010-06-03 |
| 20100137228 | DRUGS, FOODS OR DRINKS WITH THE USE OF ALGAE-DERIVED PHYSIOLOGICALLY ACTIVE SUBSTANCES -
Medicinal compositions for treating, ameliorating or preventing diseases with sensitivity to 3,6-anhydrogalactopyranose represented by formula (1):
| 2010-06-03 |
| 20100137229 | Method Of Enhancing Lysosomal Alpha-Galactosidase A - A method of enhancing the activity of lysosomal α-Galactosidase A (α-Gal A) in mammalian cells and for treatment of Fabry disease by administration of 1-deoxy-galactonojirimycin and related compounds. | 2010-06-03 |
| 20100137230 | NEW PYRIDIN-2-ONE COMPOUNDS - The present invention relates to compounds of the formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria: | 2010-06-03 |
| 20100137231 | 6"-AMINO-6"-DEOXYGALACTOSYLCERAMIDES - This invention relates to galactosylceramide compounds. | 2010-06-03 |
| 20100137232 | COMPOSITION COMPRISING A DIURETIC AND A CARDIAC GLYCOSIDE FOR THE TREATMENT OF DNA VIRAL INFECTIONS OF THE EYE - DNA viral infections of the eye are treated or prevented by the application of a composition including a diuretic and/or a cardiac glycoside dissolved in a water/ethanol solution wherein the level of the ethanol is adjusted to be acceptable to the eye. | 2010-06-03 |
| 20100137233 | Active substance combinations with insecticides and acaricide properties - The novel active compound combinations comprising compounds of the formula (I) and spinetoram have very good insecticidal and/or acaricidal properties. | 2010-06-03 |
| 20100137234 | 10-SUBSTITUTED MACROLIDE ANTIBIOTICS - Disclosed herein are 10-desmethyl, 10 substituted-macrolides, their preparation, pharmaceutical compositions containing them, their use and methods of treatment using them. The 10-desmethyl macrolides are particularly useful as antibiotics. | 2010-06-03 |
| 20100137235 | Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics - Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. | 2010-06-03 |
| 20100137236 | Compositions Comprising a GPR109 Ligand For Treating Disorders of the Digestive Tract and/or Cancer - Pharmaceutical compositions containing an effective amount of a ligand for GPR109 to decrease intracellular cAMP levels of a subject in combination with an effective amount of a DNA methyl transferase inhibito to reduce or inhibit downregulation of GPR109 in the intestinal epithelial cells of the subject relative to a control are provided. It has been discovered that ligands for GPR109 can be used to treat one or more symptoms of cancer, inflammatory disorders, and diarrhea. Representative CPR 109 ligands include, but are not limited to butyrate, β-hydroxybutyrate, nicotinic acid, acifran, and octanoate. Suitable DNA methyl transferase inhibitors include 5-azacytidine, 5-aza-2′-deoxytidine, 1-β-D-arabinfαmosyl-5-azacytosine and dihydro-5-azacytidine. Typically, the compositions are formulated to achieve a GPR 109 ligand serum blood level of about 1 to about 1000 μM. The compositions are useful for the treatment of one or more symptoms of cancer. Preferred cancers that can be treated using the disclosed compositions include, but are not limited to colon cancer, breast cancer and leukemia. Methods for treating cancer, inflammatory disorders, and diarrhea are also provided. | 2010-06-03 |
| 20100137237 | PROCESS FOR THE PREPARATION OF AN (RP)-8-SUBSTITUTED CAMPS - This invention relates to a process for the preparation of an (Rp)-8-substituted adenosine-3′,5′-cyclic phosphorothioic acid, or a salt or ester thereof, which comprises P-amidating 8-bromoadenosine-3′,5′-cyclic phosphoric acid, and reacting the P-amidate with a base and with carbon disulphide to yield (Rp)-8-bromoadenosine-3′,5′-cyclic phosphorothioic acid or a salt or ester thereof. | 2010-06-03 |
| 20100137238 | Method For Increasing Hair Growth - The present invention provides a method for stimulating hair growth, which comprises applying a composition containing at least one energy-inducing compound selected from the group consisting of 5′-AMP and ATP. Such a composition is particularly effective in increasing the DNA synthesis in dermal papilla cells. | 2010-06-03 |
| 20100137239 | GEMCITABINE COMBINATION THERAPY - The present invention provides compositions and methods for the treatment of cell proliferative disorders using at least one DAC inhibitor and gemcitabine. | 2010-06-03 |
| 20100137240 | USE OF NUCLEOSIDE DERIVATIVES AS ANTI-KOI HERPES VIRUS IN FISH - The present invention relates to the use of N-phosphonylmethoxyethyl nucleoside analogs for manufacturing a medicament for the treatment or prevention of Koi Herpes virus infections in fish, especially in carps. | 2010-06-03 |
| 20100137241 | IMIDATED BIOPOLYMER ADHESIVE AND HYDROGEL - Biologically compatible polymers carry an imide and can be used as an adhesive, a hydrogel or both. A second biologically compatible polymer reactive with the imidated polymer can be used therewith to seal openings. | 2010-06-03 |
| 20100137242 | PAROMOMYCIN SUPPLEMENTED FEEDINGSTUFFS FOR POULTRY SPECIES AND USE THEREOF FOR PROPHYLAXIS OF HISTOMONIASIS, REDUCTION OF THE HORIZONTAL SPREADING OF HISTOMONIASIS, AND FOR IMPROVED WEIGHT GAIN AND FEED CONVERSION - Disclosed is the continuous supplementation of poultry feeding stuffs with paromomycin and the resulting effects of prophylaxis against histomoniasis, ensuing decrease of mortality and the reduction of horizontal spreading of the disease. Also observed are improved zoo-technical performances, increase in weight gain and feed efficiency, both in healthy as well as diseased birds. | 2010-06-03 |
| 20100137243 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents - Compounds of Formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, and compounds as shown in Formula (I) wherein C is for example (D), (E), (F); wherein A and B are independently selected from (i) and (ii); R | 2010-06-03 |
| 20100137244 | PREPARATION AND UTILITY OF HMG-COA REDUCTASE INHIBITORS - Chemical syntheses and medical uses of novel modulators of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and diastereomeric mixtures of isomers, individual diastereomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of hypercholesterolemia, dyslipidemia, coronary artery disease, atherosclerosis, metabolic syndrome, a hyperproliferative disease such as colorectal cancer, prostate cancer, and melanoma, a neurodegenerative disease such as cerebral ischemia, Alzheimer's disease, and Parkinson's disease are described. | 2010-06-03 |
| 20100137245 | Heteerocyclyl-substituted thiazoles as crop protection agents - Heterocyclyl-substituted thiazoles of the formula (I), | 2010-06-03 |
| 20100137246 | Anti-inflammatory compositions and methods - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that modulate at least one inflammatory response or reaction. According to various embodiments, the compositions, methods, devices, and systems relate to modulating one or more of Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes. | 2010-06-03 |
| 20100137247 | Anti-inflammatory compositions and methods - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that modulate at least one inflammatory response or reaction. According to various embodiments, the compositions, methods, devices, and systems relate to modulating one or more of Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes. | 2010-06-03 |
| 20100137248 | BORON-CONTAINING COMPOUNDS, USES AND PREPARATION THEREOF - There are provided compounds of formulas (I) to (XIV) and compositions comprising such compounds. Such compounds and compositions are particularly useful for treating inflammation and/or pain, or for water treatment. | 2010-06-03 |
| 20100137249 | COMPOSITIONS FOR REGULATING OR MODULATING QUORUM SENSING IN BACTERIA, METHODS OF USING THE COMPOUNDS, AND METHODS OF REGULATING OR MODULATING QUORUM SENSING IN BACTERIA - The present disclosure encompasses compounds and compositions that are useful as specific AI-2 antagonists for the control of bacterial quorum sensing. Although the AI-2 antagonists according to the present disclosure may not have bactericidal effect, their ability to attenuate virulence, drug resistance, and/or biofilm formation have therapeutic benefits. In addition, the AI-2 antagonists of the present disclosure can also be used as tools to probe bacterial AI-2 functions. The present disclosure also encompasses methods for inhibiting or attenuating microbial virulence, biofilm formation, and drug resistance. The methods are suitable for preventing bacteria from accruing and forming extensive biofilms that may be a health or hygiene hazard or a physical issue, such as in the blockage of water or fuel lines. | 2010-06-03 |
| 20100137250 | NAPHTHYLACETIC ACIDS - The invention is concerned with the compounds of formula I: | 2010-06-03 |
| 20100137251 | Functional Role for Cannabinoids in Autonomic Stability During Sleep - The present invention relates generally to pharmacological methods for the prevention or amelioration of sleep-related breathing disorders via administration of cannabimimetic agents and combinations thereof. | 2010-06-03 |
| 20100137252 | Ophthalmic composition - The ophthalmic composition of the invention comprises (A) lecithin and (B) at least one refrigerant selected from the group consisting of camphor, borneol, eucalyptus oil, and bergamot oil. In the ophthalmic composition, the odor of lecithin is efficiently masked by the refrigerant. The odor of lecithin after aging is also masked by the refrigerant. Since the refrigerant is volatile, the concentration thereof in a composition tends to gradually decrease. It is surprising that the odor of lecithin after aging can nevertheless be masked. | 2010-06-03 |
| 20100137253 | THERAPEUTIC COMPOUND AND TREATMENTS - Compositions and uses associated with the MT477 family of compounds are disclosed. Particular structural features and properties of the compounds are described in detail. Uses include administering an MT477 family member to a patient for therapeutic purposes. Compositions include chemicals belonging to the MT477 family and pharmaceuticals that contain such chemicals. | 2010-06-03 |
| 20100137254 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS - Phosphoramidate alkylator prodrugs can be used to treat cancer when administered along or in combination with one or more anti-neoplastic agents. | 2010-06-03 |
| 20100137255 | CREATINE PHOSPHATE ANALOG PRODRUGS, COMPOSITIONS AND USES THEREOF - Membrane permeable prodrugs of creatine phosphate analogs, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate analogs, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate analogs, or pharmaceutical compositions thereof are disclosed. | 2010-06-03 |
| 20100137256 | Device and Method for Treating Human Body - A method for contouring the body by destroying adipose tissue is disclosed. This method can reduce the circumference of the treated area, improve skin contour irregularities and smooth the appearance of the skin surface. The method is also used as a body treatment before and after a liposuction procedure. | 2010-06-03 |
| 20100137257 | METHOD FOR ALLEVIATING PAIN USING SPHINGOSINE-1-PHOSPHATE AND RELATED COMPOUNDS, AND ASSAYS FOR IDENTIFYING SUCH COMPOUNDS - Methods for alleviating pain comprising administering to a subject sphingosine-1-phosphate, functional fragments and derivatives thereof, and other compounds, and assays for identifying such compounds. | 2010-06-03 |
| 20100137258 | THIOPHOSPHI(O)NIC ACID DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS - The invention relates to thiophosphi(o)nic acid derivatives having formula (I) wherein. M is a [C(R | 2010-06-03 |
| 20100137259 | COMPOUND FOR INHIBITING TRPA1 FUNCTION AND USE THEREOF - The present invention relates to a TRPA1 activation inhibitor, more precisely a TRPA1 activity inhibitor containing isopentenyl pyrophosphate and a method for inhibiting pain containing the step of administering isopentenyl pyrophosphate to a subject. Isopentenyl pyrophosphate of the present invention can regulate pain caused by TRPA1, so that it can be effectively used for the development of a pain inhibitor which is effective but has less side effects. | 2010-06-03 |
| 20100137260 | COMPOUND FOR INHIBITING TRPV3 FUNCTION AND USE THEREOF - The present invention relates to a TRPV3 (transient receptor potential vanilloid 3) activity inhibitor, more precisely to a method for inhibiting TRPV3 activity including the step of treating isopentenyl pyrophosphate and a method for treating skin disease containing the step of administering isopentenyl pyrophosphate to a subject with skin disease or applying the same on the skin of the subject. Isopentenyl pyrophosphate of the present invention controls increase of sensory cell reactivity to current or migration and proliferation of skin cells induced by TRPV3, so that it can be effectively used for the development of a pain reliever or a therapeutic agent for skin disease. | 2010-06-03 |
| 20100137261 | Method for treating aortic stenosis with non-antibacterial tetracycline formulations - The present invention is for a method for treating aortic stenosis in a mammal in need thereof. The method comprises administering an effective amount of a non-antibacterial tetracycline formulation, to the mammal. | 2010-06-03 |
| 20100137262 | Low Calcemic, Highly Antiproliferative, Analogs of Calcitriol - The disclosure provides compounds, compositions and methods using these compounds and compositions to stimulate the differentiation of cells and inhibit excessive cell proliferation of certain cells, including cancer cells and skin cells, which may be useful in the treatment of diseases characterized by abnormal cell proliferation and/or cell differentiation such as leukemia, myelofibrosis and psoriasis without the well known effect on calcium metabolism, which gives rise to hypercalcemia. | 2010-06-03 |
| 20100137263 | ASSAY FOR THE DETECTION OF BIOMARKERS ASSOCIATED WITH PREGNANCY RELATED CONDITIONS - The invention relates to screening methods for determination of the risk of preterm delivery and/or pregnancy associated conditions. The methods involve detection of the level of one or more biomarkers in a biological sample from the patient. In particular, in embodiments of the invention there are provided methods for determining the risk of pre-eclampsia and other hypertensive disorders, and intrauterine growth retardation (IGUR). | 2010-06-03 |
| 20100137264 | PROGESTATIONAL 3-(6,6-ETHYLENE-17B-HYDROXY-3-OXO-17A-PREGNA-4-ENE-17A-YL)PROPIONIC ACID G-LACTONES - Described herein are 3-(6,6-ethylene-17β-hydroxy-3-oxo-17α-pregna-4-ene-17α-yl)propionic acid γ-lactone derivatives having progestational and aldosterone antagonistic activity. Also described herein are methods of preparing and using these novel compounds. | 2010-06-03 |
| 20100137265 | TREATMENT OF CONDITIONS RELATING TO HORMONE DEFICIENCIES BY ADMINISTRATION OF PROGESTINS - The present invention includes methods for preventing endometrial hyperplasia associated with estrogen therapy through the administration of a progestin agent. The methods presented may include starting the administration of a progestin agent at a high dose, and then lowering the dose. | 2010-06-03 |
| 20100137266 | TREATMENT OF INSULIN RESISTANCE AND DISORDERS ASSOCIATED THEREWITH - The present invention provides the use of an LXR antagonist, or a physiologically-acceptable pro-drug therefor, in the manufacture of a medicament for combating insulin resistance or a disorder associated therewith. Further provided is a compound being an ester or carbamate of a hydroxycholesterol, a pharmaceutical composition of such a compound or its use in therapy. | 2010-06-03 |
| 20100137267 | FORMULATIONS FOR TREATMENT OF ADIPOSE TISSUE, CUTANEOUS TISSUE AND DISORDERS, AND MUSCULAR TISSUE - Compositions, formulations, methods, and systems for treating regional fat deposits and fat-related conditions, dermal conditions, and muscular conditions. Methods comprise administering a composition comprising at least one compound that reduces desensitization of beta adrenergic receptors, for example a glucocorticosteroid, and/or at least one long-acting beta-2 adrenergic receptor agonist, for example, formoterol. Compositions to be administered include sustained release formulations comprising at least one long-acting beta-2 adrenergic receptor agonist, at least one compound that reduces desensitization of beta adrenergic receptors, or both in a sustained crystalline microparticle form. | 2010-06-03 |
| 20100137268 | PHTHALAZINONE MODULATORS OF H1 RECEPTORS AND/OR LTC4 RECEPTORS - The present invention relates to new phthalazinone modulators of H1 receptor activity and/or modulators of LTC4 production, pharmaceutical compositions thereof, and methods of use thereof. | 2010-06-03 |
| 20100137269 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens: Synehesis, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity - Described are steroidal C-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods for their synthesis are also described, which include methods having a step of nucleophilic vinylic “addition-elimination” substitution reaction of 3β-acetoxy-17-chloro-16-formylandrosta-5,16-diene or analogs thereof and benzoazole or pyrimidinoazole nucleophiles and methods having a palladium catalyzed cross-coupling reaction of 17-iodoandrosta-5,16-dien-3β-ol or analogs thereof with tributylstannyl diazines. The compounds are potent inhibitors of human CYP17 enzyme as well as potent antagonists of both wild type and mutant androgen receptors (AR). The compounds are useful for the treatment of human prostate cancer. | 2010-06-03 |
| 20100137270 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS - A variety of diseases and disorders associated with the metabolic pathways involved in the activities of cyclooxygenase and the synthesis of prostaglandins, for example type 2 diabetes mellitus and its sequelae, ischemic vascular diseases, pain associated with inflammation, inflammatory skin conditions, spinal cord injury, peripheral neuropathy, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis, as well as various types of cancer may be treated or prevented by the use of an agent which selectively enhances production of 15-deoxy-prostaglandin J2. | 2010-06-03 |
| 20100137271 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMINISTRATION OF HYDROPHOBIC DRUGS - Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, and a surfactant. The synergistic effect between the hydrophobic drug and the solubilizer results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharmaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided. | 2010-06-03 |
| 20100137272 | Zinc Salt Of Isothiazolone Compound, Method For Reducing Irritation Caused By Isothiazolone Compound, Antibacterial and Antifungal Method Using Zinc Salt of Isothiazolone Compound, and Antibacterial and Antifungal Composition - There are provided, according to the present invention, a zinc salt of an isothiazolone compound represented by the following formula (1); a method for reducing the extent of irritation by converting the isothiazolone compound represented by the formula (1) into a zinc salt; an antibacterial and antifungal method using the zinc salt; and an antibacterial and antifungal composition including at least one kind of the zinc salt, | 2010-06-03 |
| 20100137273 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions - Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described. | 2010-06-03 |
| 20100137274 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION - The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) | 2010-06-03 |
| 20100137275 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE - The present invention relates to the novel triaminopyrimidine derivatives of formula (I) in which R1, R2, W, R3, R4, and R5 are variable groups. These products have a Cdc25-phosphatase-inhibiting activity. The invention also relates to a process for synthesizing these compounds and also to therapeutic compositions containing these products and to the use thereof as medicaments. | 2010-06-03 |
| 20100137276 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE - Compounds of formula (I), and salts and solvates thereof are provided: | 2010-06-03 |
| 20100137277 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS - The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y | 2010-06-03 |
| 20100137278 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS - Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like. | 2010-06-03 |
| 20100137279 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS - The present invention is directed to novel 4-methylpyridopyrimidinone compounds of Formula (I), | 2010-06-03 |
| 20100137280 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR - The present invention relates to compounds of formula (I) | 2010-06-03 |
| 20100137281 | HETEROCYCLIC COMPOUND AND USE THEREOF - The present invention aims to provide a compound having superior pharmacological action, physicochemical properties and the like, which is useful for the prophylaxis or treatment s of circulatory diseases such as hypertension, cardiac diseases, arteriosclerosis, renal diseases, cerebral apoplexy and the like and/or metabolic diseases such as hyperlipidemia, obesity, diabetes and the like, central nervous disorders such as cerebral infarction and the like, mental diseases such as dementia, depression and the like, and the like. | 2010-06-03 |
| 20100137282 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS - Tricyclic nitrogen containing compounds and their use as antibacterials. Z | 2010-06-03 |
| 20100137283 | INHIBITORS OF THE HIV INTEGRASE ENZYME - The present invention is directed to compounds of formula (I), | 2010-06-03 |
| 20100137284 | Compositions for the Treatment and Prevention of Heart Disease and Methods of Using Same - The combination of nitric oxide generating compounds which are not dependent upon aldehyde dehydrogenase for bioactivation, or are specifically targeted to nNOS or the sarcoplasmic reticulum of cardiac muscle cells, and xanthine oxidase inhibitors are effective in the treatment of heart disease, specifically congestive heart failure and ischemic coronary disease. This treatment is particularly effective in patients who have particularly heavy oxidative burdens, e.g. diabetics, patients with lung disorders, patients with sickle cell anemia and patients of Asian descent. | 2010-06-03 |
